Examining blood biomarkers and cognitive disorders in ICU survivors
The Relationship Between Neurological Blood-based Biomarkers and Mid-term Cognitive Disorders in Critically Ill Survivors.
This study is trying to see if certain blood markers can help us understand cognitive problems in patients who have survived a long stay in the ICU.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Liege Academic / other |
| Locations | 1 site (Liège) |
| Trial ID | NCT05953311 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the relationship between neurological blood biomarkers and cognitive disorders in patients who have survived an intensive care unit (ICU) stay. It focuses on critically ill patients who are expected to stay in the ICU for at least seven days due to conditions such as sepsis or acute respiratory distress syndrome. The study will involve blood analyses to measure specific biomarkers and cognitive tests to assess cognitive function during the three months following ICU discharge.
Who should consider this trial
Good fit: Ideal candidates are French-speaking patients who have been in the ICU for at least seven days due to severe medical conditions.
Not a fit: Patients with pre-existing cognitive disorders, neurological diseases, or sensory impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management of cognitive disorders in ICU survivors.
How similar studies have performed: While studies on cognitive disorders in ICU survivors exist, the specific focus on blood biomarkers in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Anticipated ICU stay of at least 7 days for sepsis, acute respiratory distress syndrome, severe burns * French speaking Exclusion Criteria: * hearing loss or blindness * mental retardation * known cognitive disorders or dementia * ICU admission for neurological disease * refusal
Where this trial is running
Liège
- University Hospital of Liège — Liège, Belgium (Recruiting)
Study contacts
- Study coordinator: Anne-Françoise Rousseau, MD, PhD
- Email: afrousseau@chuliege.be
- Phone: +3243234776
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.